Loading...

RNTX REIN THERAPEUTICS INC US FDA Inspections 8-K Filing

RN T

RNTX

REIN THERAPEUTICS INC

(RNTX)

2025 8-K

Capital Raise Activity

Board Resignation

Funding Agreement

Agreement Termination

FDA Trial Clearance

Funding Agreement Details

EMA Approval Granted

FDA Update Received

Financial Agreement Update

Clinical Trial Announcement

Equity Offerings

Regulatory Compliance

Management Changes

Financial Statements

Warrant Transactions

Accountant Change

Financial Results

Annual Meeting Results

Financial Results

Equity Distribution Agreement

Shareholder Director Nomina...

Management Change

Financial Results Announcement

Underwriting Agreement for ...

Clinical Trial Results

Financial Results Announcement

Resignation and Appointment...

Management Change

Resignation and Compliance ...

Annual Meeting Results

Acquisition through Merger

Notice of Failure to Satisf...

Merger Agreement

Workforce Reduction and Tri...

External Links:

On November 3, 2025, Rein Therapeutics, Inc. announced FDA clearance to resume its U.S. Phase 2 Trial of LTI-03 for treating idiopathic pulmonary fibrosis.

AI Assistant

REIN THERAPEUTICS INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.